

Effect of Clomiphene Citrate on Rectus Femoris Histology and Spermatogenesis in rats

SIDRA AFAQ¹, MOHAMMAD TAHIR², K.P LONE³, WAQAS LATIF⁴

ABSTRACT

Aim: Clomiphene citrate, used to treat PCOS in female, has both antiestrogenic and estrogenic properties. It has also been used by athletes to counteract the testosterone induced estrogenic effects and increases endogenous testosterone level. Present study was designed to observe the effect of clomiphene citrate on skeletal muscle histology and spermatogenesis in rats.

Methods: Twenty four rats were divided randomly into three groups. Group A, control, received 100 μ l of corn oil for 6 days. Group B received 10mg/kg body weight clomiphene citrate intramuscularly everyday for 6 days. Group C received the same dose as group B but every 5th day for 30 days. Animals were sacrificed 24 hours after last injection. Testes and muscle were removed, weighed. H&E sections were obtained and studied.

Results: No significant difference was found in diameter and number of muscle fibers, Johnsen's score and serum testosterone level in all groups. In group B, the diameter of leydig cells and serum LH level were high.

Conclusion: Clomiphene citrate significantly increased LH level in group receiving clomiphene citrate, however, no significant decrease in level of serum testosterone was seen in both treated groups, a probable reason for no effect on muscle mass.

Keywords: Clomiphene citrate, estrogen receptor modulator, hpothalamo-pituitary-gonadal axis, serum testosterone, serum leutinizing hormone.

INTRODUCTION

Clomiphene citrate (CC) is a chlorethylene derivative with chemical name of 1-[*p* (β diethylaminoethoxy) phenyl]-1, 2-diphenylchloroethylene¹. It has both estrogenic and antiestrogenic properties and hence is termed as estrogen receptor modulator². These properties are due to the presence of two isomers namely: enclomiphene and zuclomiphene. The former is estrogen antagonist and the latter is estrogen agonist³. It is absorbed well when taken by oral route and has a half life of 5-7 days².

Clomiphene citrate is used for treatment of polycystic ovarian syndrome (PCOS) and infertility due to anovulatory cycles¹. Being similar to estrogen in structure, clomiphene citrate binds to estrogen receptors in hypothalamus for a longer period of time⁴ and increases the concentration of gonadotrophin releasing hormones (GnRH) in the blood. GnRH in turn stimulates secretion of FSH and LH⁵.

Common side effects of this drug are hot flushes, constipation, headache and reversible hair loss. It has also been seen to cause depression,

fatigue, weight gain and increased urinary frequency². Visual symptoms such as diplopia, blurred vision, scotoma are uncommon but requires stoppage of treatment⁶.

Clomiphene citrate has also been used by athletes, who use exogenous androgens as dietary supplements to enhance muscle strength^{7,8}. Clomiphene citrate, in these cases was used to reverse the adverse effects of exogenous androgens that lead to decrease in serum testosterone levels and caused hypogonadism^{7,8}. Clomiphene citrate, acting as an estrogen antagonist, inhibits the negative feedback loop of exogenous testosterone on hypothalamus and leads to a rise in serum testosterone level⁷.

When testosterone levels are high, they inhibit the release of LH and to some extent FSH⁹, which are the main hormones that regulate spermatogenesis¹⁰. Leydig cells produce testosterone under the influence of LH. Sertoli cells, under the influence of FSH, produce aromatase which converts testosterone to estradiol in the testes. LH causes conversion of pregnenolone, an endogenous steroid, to testosterone in leydig cells¹¹. Estradiol, locally produced in the testis, is also thought to be involved in this negative feedback loop known as hypothalamic-pituitary-testicular axis⁹. In men, estradiol (produced by aromatization of testosterone) inhibits secretion GnRH from

¹Research Scholar M.Phil Anatomy, UHS, Lahore

²Professor & Head of Anatomy, UHS, Lahore

³Professor & Head of Physiology, UHS, Lahore

⁴Biostatistician, QEC, UHS, Lahore

Correspondence to Prof. Mohammad Tahir, Email: babari1@gmail.com Tel. 92-4299231304-9/ Ext. 339

hypothalamus and Gonadotrophin from pituitary¹². In view of these effects, it was decided to study the effect of clomiphene citrate on muscle and testicular physiology in albino rats.

MATERIAL AND METHODS

Twenty four (24) healthy adult male Wistar rats 6-8 weeks of age, weighing between 200-250gm, were procured from animal house, University of Health Sciences, Lahore. Rats were caged and kept under controlled temperature of $23\pm 2^{\circ}\text{C}$ and humidity of $55\pm 5\%$ and light-dark cycles of 12 hours each. Animals were given standard rat chow and water ad libitum and allowed to acclimatize for 3-4 days before the start of the experiment. All procedures were carried out in a clean and aseptic environment approved by ethical committee of University of Health Sciences. Weight of all the rats was recorded at the beginning and at the end of experimental period.

Animals were divided randomly into three groups A, B and C of eight rats each.

Group A was given 100 μl corn oil intramuscularly in quadriceps femoris muscle everyday for 6 days.

Group B was treated with 10mg/kg clomiphene citrate⁴ in 100 μl of corn oil intramuscularly in quadriceps femoris muscle everyday for 6 days (acute effect).

Group C was treated with 10mg/kg clomiphene citrate⁴ in 100 μl of corn oil intramuscularly in quadriceps femoris muscle every 5th day for 30 days (chronic effect).

The drug was obtained from Sigma (USA). The required dose was prepared by dissolving appropriate amount of clomiphene citrate in the minimum volume of isopropyl alcohol and this solution was later suspended in 100 μl of corn oil and a homogenous mixture of required dose was prepared. The mixture was kept overnight so that alcoholic portion evaporated as much as possible.

Rats in groups A and B were sacrificed on 7th day and group C one day after the last injection after being anesthetized with ether-soaked cotton. Each animal was weighed and blood drawn through cardiac puncture. Testes and Quadriceps femoris muscle were removed weighed to the nearest mg and were fixed in Bouine's solution for 48 hours. The tissues were washed three times with 50% alcohol and kept in it for 24 hours. They were processed in an automated processor, cleared in xylene and embedded with paraffin. Five micron thick sections were cut using Leica automatic microtome. Slides from each animal were stained with hematoxylin and eosin (H&E). Microscopic parameters included diameter of muscle fibers, number of muscle fibers, diameter of leydig cells and Johnsen's scoring.

Johnsen scoring was done in ten tubules from each block (animal) and mean calculated. Diameter of leydig cells was also taken¹³. Diameter was calculated along two axes right angle to each other for 20 different cells from a slide and mean was calculated. Diameter of ten muscle fibers was calculated in three different fields along minor and major axis as done by Aughesteen et al. (2006)¹⁴. Mean value was calculated from these measurements. Similarly, muscle fibers were counted in the three non overlapping fields before calculating the mean. LH and testosterone were measured by ELISA using kits for rat serum (Glory, USA). Data were analyzed using SPSS 21. One way ANOVA followed by post-hoc tukey test was applied to assess the difference between groups. Kruskal Wallis test was applied for data that were not distributed normally e.g., Johnsen scoring, serum testosterone level and serum LH levels. A p-value of ≤ 0.05 was considered statistically significant.

RESULTS

No change in gross features of testes was observed in any of the three groups (A, B and C) of rats. Mean weight of animals in group A at start and end of experiment was 227.75 ± 8.87 and 240.87 ± 12.05 gm respectively; that of group B was 221.62 ± 5.15 and 234 ± 12.60 gm respectively and in group C was 224.75 ± 4.09 and 233.87 ± 6.2 respectively. There was no statistically significant difference ($p > 0.05$) in weight of animals at start and end of experiment.

Combined weight of testes at the end of experiment in groups A, B and C was $2.51\pm 0.43\text{mg}$, $2.29\pm 0.12\text{mg}$ and $2.39\pm 0.15\text{mg}$ respectively. These weights were not different from each other (ANOVA; NS). Similarly, combined weight of quadriceps femoris in groups A, B and C was $3.56\pm 0.15\text{mg}$, $3.54\pm 0.12\text{mg}$ and $3.42\pm 0.14\text{mg}$ respectively were not different (ANOVA; NS).

No effect on spermatogenesis was seen after treatment with clomiphene citrate in groups B and C as compared with control. Johnsen score was calculated as follows¹⁴:

- | | |
|----|--|
| 10 | Complete spermatogenesis. |
| 9 | Many spermatozoa but germinal epithelium disorganized. |
| 8 | few (5-10) spermatozoa. |
| 7 | No spermatozoa but many spermatids. |
| 6 | No spermatozoa but few (5-10) spermatids. |
| 5 | No spermatozoa or spermatids but many spermatocytes. |
| 4 | Few spermatocytes (5-10), no spermatids. |
| 3 | Only spermatogonia. |
| 2 | No germ cells but only setoli cells. |
| 1 | No cells. |

Based on these parameters, no difference in Johnsen's score (10.0 ± 0.46) was observed in any of the group of the study.

Mean diameter of leydig cells in three groups was $13.43 \pm 0.30 \mu\text{m}$, $13.93 \pm 0.39 \mu\text{m}$ and $13.37 \pm 0.49 \mu\text{m}$ respectively. One way ANOVA showed a significant difference among the mean diameter of three groups ($p = 0.02$). Post Hoc Tuckey test revealed that diameter of leydig cells in group B was greater than that in group C.

Mean diameter of muscle fibers in group A, B and C was $28.03 \pm 0.84 \mu\text{m}$, $28.21 \pm 1.72 \mu\text{m}$ and $27.09 \pm 1.03 \mu\text{m}$ respectively. These values were not different from each other (ANOVA, NS).

Similarly, no difference was observed in number of muscle fibers counted at X40 in three (28.41 ± 3.02 , 28.96 ± 2.04 and 28.90 ± 2.10 respectively) study groups.

Mean serum testosterone level in group A, B and C was $0.10 \pm 0.18 \text{ng/ml}$, $0.72 \pm 0.09 \text{ng/ml}$ and $0.39 \pm 0.44 \text{ng/ml}$ respectively. The difference in serum testosterone was not significant statistically.

Mean serum LH level in group A, B and C was $6.62 \pm 4.73 \text{mIU/ml}$, $11.11 \pm 9.90 \text{mIU/ml}$ and $2.40 \pm 2.96 \text{mIU/ml}$ respectively. One way ANOVA ($p = 0.02$) showed statistically significant difference among the groups. Post-hoc test showed that group B values were significantly higher than that of group C values. No difference was seen between groups A and B and A and C.

Figures:

Fig. 1: Photomicrograph of transverse section of testis from group A showing seminiferous tubules lined by spermatogonia (SG), primary spermatocytes (PS), spermatid (SD), spermatozoa (SZ). leydig cells (LC) are seen scattered between tubules in interstitium and nuclei of leydig cells (LN) are also seen. Diameter of leydig cells was calculated by measuring diameter along two axes right angle to each other and calculating the mean. H&E stain. X400.




Fig. 2: Photomicrograph of transverse section of testis from group B showing leydig cells (LC) having greater diameter than group A and C, scattered between tubules in interstitium, nuclei of leydig cells (LN) are also seen. Seminiferous tubules were seen lined by germinal epithelium consisting of spermatogonia (SG), primary spermatocytes (PS), spermatid (SD) and spermatozoa (SZ). H&E stain. X400





Fig. 3: Photomicrograph of transverse section of testes from group C showing leydig cells (LC) having same diameter as group A but smaller than group B, scattered between tubules in interstitium. Nuclei of leydig cells (LN) are also seen. Seminiferous tubules are seen lined by germinal epithelium consisting of spermatogonia (SG), primary spermatocytes (PS), spermatid (SD) and spermatozoa (SZ). H&E stain. X400.



Source(s) of support: drug was obtained from Sigma pharmaceuticals, the study was funded by University of Health Sciences, Lahore. Equipment was used from laboratory of University of Health Sciences.

DISCUSSION

In the present study intramuscular injections of clomiphene citrate in oil at a dose 10mg/kg body weight per day for 6 days (60mg total dose) consecutively or every 5th day did not change the animal ($p=0.34$), testes ($p=0.29$) and muscle weight ($p\text{-value}=0.14$).

Microscopic examination of testes showed normal spermatogenesis in experimental groups. Johnsen scoring was comparable among the groups and all the layers of germinal epithelium were seen and were comparable with lumen filled with spermatids. These findings, are different from the results of Bharti et al¹⁵, who reported impairment of spermatogenesis after treating rats with 5mg clomiphene citrate every 5th day for 30 days. This difference was probably due to high dose⁴ of drug used by them.

Treatment with clomiphene citrate increased the diameter of leydig cells in group B that received daily dose of clomiphene citrate (10mg/kg) for 5 days, while in group C the leydig cell diameter was comparable to that of control group. Flickinger et al¹⁶. observed a decrease in the size of leydig cells after daily treatment with 2.5, 3.5 and 5mg/100gm body weight per day clomiphene citrate for a long duration of 12 weeks. As such our results are also different from the results of Flickinger et al¹⁶. This may be due to the long duration of treatment and the higher dose of clomiphene citrate used or rat strain was different in the two studies.

Analysis of serum testosterone and LH level estimated by ELISA revealed an increase in serum LH levels in group B as compared with control and group C. These results are in agreement with the results of Santen et al.¹⁷ who treated men with 100mg clomiphene citrate (dose) daily for 7 days and observed an increase in serum LH levels. Increased serum LH levels in these two studies, in men and rats after treatment with clomiphene citrate are presumably due to the antagonistic action of clomiphene citrate on hypothalamus-gonadal axis. Although, serum LH level decreased in group C of the present study, however, the difference between control and group C was insignificant. Bharti et al¹⁵ also observed a decrease in serum LH levels of rats after 30 days of treatment with clomiphene citrate but the decrease was significant in their study. According to them, a decrease in LH level in their study was due to potentiation of estrogen agonistic property (negative effect on testis by clomiphene citrate) of clomiphene citrate rather than estrogen antagonist and as described earlier, due to high dose of clomiphene citrate used.

In the present study, serum LH levels were raised only in group B receiving clomiphene citrate on consecutive days (acute effect). This effect was probably due to the two isomers of clomiphene citrate, i.e., enclomiphene and zuclomiphene. Enclomiphene is potent antagonist of E₂ as compared with zuclomiphene which is E₂ agonist. Enclomiphene also has a shorter half life¹. Group B received daily dose of clomiphene citrate and on

premise that it produced a persistent level of enclomiphene, thus increasing serum LH level. The group C, that received drug every 5th day did not show any rise in serum LH level showing enclomiphene in the drug clomiphene citrate was cleared from body due to its shorter half-life.

Statistically insignificant difference in serum testosterone level was observed in both the experimental groups (p=0.28). This finding contradicts the earlier report by Guay et al. (19) who treated hypogonadal men with 50mg clomiphene citrate for 4 months and observed an increase in serum testosterone levels. Bharti et al¹⁵ observed a decrease in serum testosterone levels after treatment of male rats with 5mg clomiphene citrate every 5th day for 30 days. These authors suggested that this decrease was due to estrogen agonistic action of clomiphene citrate at the estrogen receptor level.

In the current investigation, statistically insignificant difference was observed in diameter of muscle fibers (p=0.18) and number of muscle fibers (p=0.88). An increase in muscle mass seen after exogenous testosterone treatment was reported by Bhasin et al¹⁹ who observed increase in muscle mass in men treated with 100mg exogenous testosterone, weekly, intramuscularly for 10 weeks. Since no effect on the serum testosterone was observed in the present study, no changes in the muscle mass or number are expected. However, detailed studies on variable duration and concentration are required to see the effect on muscle related parameters.

CONCLUSION

Present study indicates a rise in serum LH level and leydig cell diameter in adult albino rats with daily treatment with clomiphene citrate for 6 days. However, no rise in serum testosterone level was seen. This can be useful in treating hypogonadism and increasing muscle mass if serum testosterone level increase after treatment for long duration. A long-term experiment may be designed, using different doses and treatment duration of clomiphene citrate to see if statistically significant changes in testosterone level and other hormone are observed which can affect muscle related parameters like mass and muscle strength.

Acknowledgement: All praise is for Allah, The most Merciful and Beneficial. I am highly obliged to Prof. Dr. Muhammad Tahir, whose steering leadership and guidance has helped me in cherishing my dreams. I am also thankful to Maj. Gen. (Rtd). Prof. Dr. Muhammad Aslam, Vice chancellor, University of Health Sciences. I thank my co-supervisor, Prof. Dr. Khalid Pervaiz Lone, who has guided me throughout my research and enlightened me with his knowledge.

I also thank Dr. Nosheen Omer and Dr. Alia Amin for reviewing my study.

I am thankful to Mr. Waqas Latif who helped me in understanding statistics; Mrs. Bushra Faisal, Mr. Rizwan Ali and Mr. Saqib Hussian who helped me in practical work in laboratory.

REFERENCES

1. Dickey RP and Hotkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Rev. 1996; 2(6):483-506.
2. Chrousos GP. The gonadal hormones and inhibitors. In: katzung, B. G., Masters, S. B. and Trevor, A. J. eds. Basics and clinical pharmacology. 12th ed. New York, NY: McGraw-Hill; 2012. Chapter 10.
3. Kumar A and Pakrasi P L. Estrogenic and antiestrogenic properties of clomiphene citrate in laboratory mice. J Biosci. 1995; 20(5):665-673.
4. Mansoor M. Effect of clomiphene citrate on fallopian tube of rats: Histological considerations and clinical implications. J Am Sci. 2013; 9(6):197-202.
5. Badawy A and Gibreal A. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCO: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol. 2011; 159(1):151-154.
6. The Practice committee of American society of reproductive medicine. Use of clomiphene citrate in women. Fertil Steril. 2006; 86(4):187-193.
7. Bickelman C, Ferries L and Eaton RP. Impotence related to anabolic steroid use in a body builder. West J Med. 1995; 162(2):158-160.
8. Burge RP, Lezi RA, Skarda ST and Eaton RP. Idiopathic hypogonadotrophic hypogonadism in a male runner is reversed by clomiphene citrate. Fertil And steril. 1997; 67(4): 783-785.
9. Melmed S, Polonsky KS, Larsen PR and Kronenberg HM, editors. Williams textbook of endocrinology. 12th ed. Philadelphia: Elsevier Saunders; 2011.
10. Holdcraft RW and Braun RE. Hormonal regulation of spermatogenesis. Int. J. Androl. 2004; 27(6):335-342.
11. Ewing LL, Wing TY, Cochran RC, Kromann N and Zikrin BR. Effect of leutinizing hormone on leydig cell structure and testosterone secretion. Endocrinol. 1983; 112(5):1763-1769.
12. Ros CT and Averbeck MA. Twenty five milligram of clomiphene citrate presents positive effect on treatment of male testosterone deficiency. Int Braz J Urol. 2012; 38(4):512-518.
13. Turkstra JA, Vander Meer FJUM, Knaap J, Rottier PJM, Teers KJ, Colenbrander B and Meloen RH. Effect of GnRH immunization in sexually mature pony stallions. Anim Reprod Sci. 2005; 86(3-4):247-259.
14. Aughsteen AA, Khair AM and Suleiman AA. 2006. Quantitative morphometric study of skeletal muscles of normal and streptozotocin-diabetic rats. JOP.2006; 7(4):382-389.
15. Bharti S, Misro MM and Rai U. Clomiphene citrate potentiates adverse effects of estrogen on rat testes and down regulates the expression of steroidogenic enzyme genes. Fertil Steril., 2013; 99(1):140-148.
16. Flickinger CJ. Effects of clomiphene citrate on structure of testis, epididymis and sex accessory glands of rat. Am J Anat. 1977; 149(4):533-562.
17. Santen RJ, Leonard JM, Sherins RJ, Gandy HM and Paulsen CA. 1971. Short and long term effects of clomiphene citrate on the pituitary-testicular axis. J Endocrinol Metabol. 1971; 33(6):970-979.
18. Guay AT, Jacobson J, Perez JB, Hodge MB and Velasquez F. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit?. Int J Impot Res.2003; 15(3):156-165.
19. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Philips J, Lee WP, Bunnell TJ and Casaburi R. Testosterone replacement increases fat free mass and muscle size in hypogonadal men. J Clin Endocrinol Metabol. 1997; 82(2):407-413.

ERRATUM

The name of third author **MAIRA MAHMOOD** has been wrongly printed as **Maria Mahmood** in her original article title **“Evaluation of Sodium Pumps Activity in Patients of Lahore City Suffering from Diabetes Mellitus Type 1”** published in Pakistan Journal of Medical & Health Sciences Page 643-645, Vol.10, April-June 2016 issue. This typographical error is regretted.